CRISPR-Cas systems help to protect bacteria from viruses. Several different types of CRISPR-Cas defense systems are found in bacteria, which differ in their composition and functions.

line-4088057_1280 (1)

Among them, the most studied proteins today are Cas9 and Cas12, also known as DNA or ‘gene scissors’, which have revolutionized the field of genome editing, enabling scientists to edit genomes and correct disease-causing mutations precisely.

READ MORE: CRISPR is promising to tackle antimicrobial resistance - but remember bacteria can fight back

READ MORE: Researchers deploy CRISPR to develop faster mpox testing

Researchers from the Institute of Biotechnology at the Life Sciences Center of Vilnius University – Dalia Smalakytė, Audronė Rukšėnaitė, Dr Giedrius Sasnauskas, Dr Giedrė Tamulaitienė, and Dr Gintautas Tamulaitis – have revealed the structure of the CRISPR-Cas ‘protein scissors’ found in bacteria and provided mechanistic details on how they function. The results of their study have been published in the prestigious and highly cited journal Molecular Cell.

Bacterial defense system

A team of researchers led by Dr Tamulaitis is studying the bacterial defense system CRISPR-Cas10, which acts as a sensor. When a virus attacks the bacterium, it sends a ‘message’ by synthesizing unique signal molecules called cyclic oligoadenylates. These signaling molecules are recognized by different effectors, i.e. accessory proteins in the system that enhance the bacterial defense against viruses. A recent computational analysis predicted that CRISPR-Cas10 effectors may have diverse enzymatic activities, allowing bacteria to defend themselves against viruses in multiple ways.

‘The discovery of cyclic oligoadenylates and the understanding of the mechanism of CRISPR-Cas10 have sparked great scientific interest and a breakthrough in signaling pathway research. Recently, a similar protection principle has been identified in other bacterial defense systems: CBASS, Pycsar, and Thoeris. In this study, we investigated the tripartite CalpL-CalpT-CalpS effector which is activated by CRISPR-Cas10 signaling molecules and we explained how this complex system works and how it is regulated,’ explains Dr Tamulaitis.

Key proteins

The CalpL-CalpT-CalpS effector consists of three key proteins: CalpL, which acts as a signal-recognizing ‘protein scissors’; CalpS, a protein that regulates gene expression; and CalpT, an inhibitor of the CalpS protein. The Vilnius University researchers used a combination of biochemical, biophysical, bacterial survivability assays, and cryogenic electron microscopy (cryo-EM) to study this system.

They found that when CalpL binds a molecule that signals a viral infection, it forms a polymeric filament of variable composition. The filament structure allows the CalpT-CalpS heterodimer to attach, positioning the active center of the ‘scissors’ CalpL near the inhibitor CalpT and enabling to cleave it. Once CalpT is cleaved, CalpS is released from the heterodimer and can regulate gene expression to protect the bacterium from viral infection.

Timing mechanism

One of the authors, Dalia Smalakytė, points out that the activity of the CRISPR-Cas ‘protein scissors’ is tightly regulated in time. The ‘protein scissors’ have an internal timer mechanism that is activated upon the binding of signaling molecules and filament formation. This mechanism is unique compared to other similar signal-sensing effector proteins.

Figure_protein_scissors

Source: Figure prepared by Dalia Smalakyte and Giedre Tamulaitiene.

The cryogenic electron microscope structure of the A4p-activated (green) CalpL protein filament (violet) from Candidatus Cloacimonas acidaminovorans (PDB ID: 9EYJ).

The newly discovered mechanism of the CRISPR-Cas10 system illustrates the complexity of the bacterial defense system. These studies pave the way for the practical application of the regulated CRISPR-Cas ‘protein scissors’ as a molecular indicator of infection.

The study presented in this article received funding from the Research Council of Lithuania (LMTLT), agreement No S-MIP-22-9 (Principal Investigator Dr Tamulaitis).